Biomatrix Healthcare Private Limited

Biomatrix Healthcare Private Limited, established on November 22, 2007, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24232GJ2007PTC052214. As of March 2026, Biomatrix Healthcare has an authorized capital of ₹4.5 crore and a paid-up capital of ₹4.01 crore. The company's registered office is located at Fifth Floor-502/B, Time Square Grand, Near Sindhu Bhavan, Ahmedabad, Gujarat 380059, India.

Biomatrix Healthcare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has a diverse product portfolio encompassing 15 products across six therapeutic categories. In the fiscal year 2022-2026, Biomatrix Healthcare reported a total export value of $25.7 million USD, with 676 shipments. The top five exported products are Amoxicillin ($5.0 million), Artemether ($4.0 million), Metronidazole ($3.1 million), Clindamycin ($3.1 million), and Artesunate ($2.8 million). The primary therapeutic categories include Antibiotics (37.5%), Antimalarial & Antiparasitic (26.5%), and Respiratory & OTC (16.6%). The company's portfolio concentration is notable, with the top five products accounting for 70.1% of total exports.

Biomatrix Healthcare operates a manufacturing facility located at Survey No. 624, Sarkhej-Bavla Highway, Village Rajoda, Taluka Bavla, District Ahmedabad, Gujarat 382220, India. The facility is certified by WHO-GMP, EU-GMP, and Health Canada, ensuring compliance with international quality standards. Additionally, the company adheres to US-FDA, UK-MHRA, and ANVISA regulatory requirements, reflecting its commitment to maintaining high manufacturing standards.

The leadership team at Biomatrix Healthcare includes:

• Sureshbhai Raghavjibhai Javiya: Director
• Labhuben Sureshbhai Javiya: Director
• Vijay Sureshbhai Javiya: Director
• Dinesh Pyarali Hemnani: Director

These individuals have been instrumental in guiding the company's strategic direction and operational success.

Biomatrix Healthcare has made significant strides in obtaining regulatory approvals for its products in various international markets. In October 2025, the company received site approval from the Food and Drug Administration (FDA) of the Philippines, marking a key milestone in its expansion efforts. Additionally, in the same month, Biomatrix Healthcare secured approval from the Iraqi Ministry of Health, further enhancing its presence in the Middle East. These approvals underscore the company's commitment to meeting global quality standards and expanding its footprint in regulated markets.

Biomatrix Healthcare has strategically focused on expanding its presence in emerging markets, including Africa, Latin America, Southeast Asia, and the Commonwealth of Independent States (CIS). The company's participation in international exhibitions, such as Iphex 2024 and CPHI Frankfurt 2025, has facilitated collaborations and partnerships in these regions. Furthermore, the company's manufacturing facility holds certifications from WHO-GMP, EU-GMP, and Health Canada, which are essential for market access in these regions. These certifications enable Biomatrix Healthcare to meet the regulatory requirements of various countries, thereby enhancing its market penetration in emerging economies.

Biomatrix Healthcare's geographic strategy demonstrates a balanced approach to market diversification. The company's export portfolio spans multiple regions, including Africa, Latin America, Southeast Asia, and the CIS. This diversification mitigates concentration risk and positions the company to leverage growth opportunities across different markets. The strategic direction focuses on expanding the product portfolio and obtaining regulatory approvals to strengthen the company's presence in both established and emerging markets.

Biomatrix Healthcare's manufacturing facility is registered with the US Food and Drug Administration (FDA), indicating compliance with FDA regulations. The company has also secured approvals from other regulatory bodies, including the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Brazilian Health Regulatory Agency (ANVISA), reflecting its commitment to meeting international quality standards. These approvals facilitate the company's entry into various international markets, including the United States, the United Kingdom, and Brazil.

Biomatrix Healthcare's manufacturing facility holds certifications from the World Health Organization Good Manufacturing Practice (WHO-GMP) and the European Union Good Manufacturing Practice (EU-GMP). These certifications validate the company's adherence to stringent quality standards recognized globally. The facility also complies with Health Canada regulations, further demonstrating its commitment to maintaining high manufacturing standards.

Biomatrix Healthcare operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is licensed by the CDSCO, ensuring compliance with national pharmaceutical manufacturing standards. Additionally, the company holds approvals from various state drug controllers and has obtained export No Objection Certificates (NOCs), facilitating its export operations.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Biomatrix Healthcare by regulatory authorities. The company's adherence to international quality standards and regulatory requirements underscores its commitment to maintaining a strong compliance record.

Biomatrix Healthcare operates in a competitive pharmaceutical industry, with several key players in overlapping therapeutic categories. The company's focus on obtaining international certifications and regulatory approvals positions it favorably in the global market. By diversifying its product portfolio and expanding into emerging markets, Biomatrix Healthcare aims to enhance its market share and competitive standing.

Biomatrix Healthcare's key differentiators include its comprehensive product portfolio, spanning 15 products across six therapeutic categories, and its commitment to quality, as evidenced by certifications from WHO-GMP, EU-GMP, and Health Canada. The company's strategic focus on obtaining regulatory approvals in various international markets further distinguishes it in the competitive landscape.

Biomatrix Healthcare's current strategic direction emphasizes expanding its presence in both established and emerging markets through regulatory approvals and partnerships. The company's future outlook includes further diversification of its product portfolio and strengthening its position in the global pharmaceutical industry.

Biomatrix Healthcare has demonstrated a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a commitment to quality. The company's export volume and consistency are supported by its adherence to international certifications and regulatory approvals. Reliability indicators include its compliance with WHO-GMP, EU-GMP, and Health Canada standards, as well as approvals from the FDA, MHRA, and ANVISA.

Importers should verify the following certifications when considering Biomatrix Healthcare as a supplier:

• FDA Registration: Confirm the facility's registration with the US FDA to ensure compliance with US regulations.
• WHO-GMP Certification: Verify the facility's certification by the World Health Organization to ensure adherence to international manufacturing standards.
• EU-GMP Certification: Check for certification by the European Union to confirm compliance with European manufacturing standards.
• Health Canada Certification: Ensure the facility holds certification from Health Canada to meet Canadian regulatory requirements.

These certifications can typically be verified through the respective regulatory agencies' official websites or by contacting Biomatrix Healthcare directly.

When conducting due diligence on Biomatrix Healthcare, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of certifications such as WHO-GMP, EU-GMP, and Health Canada.
• Assess Financial Health: Review the company's financial statements and credit history to evaluate financial stability.
• Evaluate Manufacturing Capabilities: